A single arm no randomized clinical trial evaluated the effectiveness and safety of once weekly semaglutide in adults with type 2 diabetes militus and obesity whose glycemic control remained inadequate despite standard therapy. participants received semaglutide for 16 weeks, beginning with 0.25mg weekly for 4 weeks followed by 0.5 mg weekly for 12 weeks. the primary outcome was the change in glycated hemoglobin, while secondary outcomes included changes in body weight, body mass index, blood glucose, blood pressure, lipid profile and treatment related adverse effects.
Inclusion Criteria:
Adults aged 18 years or older. Established diagnosis of type 2 diabetes mellitus for at least 6 months. Glycated hemoglobin (HbA1c) between 7.5% and 10.0%. Body mass index (BMI) of at least 30 kg/m². Inadequate glycemic control despite ongoing standard diabetes therapy. Willing and able to provide written informed consent.
Exclusion Criteria:
Type 1 diabetes mellitus. Gestational diabetes mellitus. Severe renal impairment, defined as an estimated glomerular filtration rate of 30 mL/min/1.73 m² or less.
Previous or current treatment with any glucagon-like peptide-1 receptor agonist.
History of chronic pancreatitis. History of pancreatic malignancy. Diabetic retinopathy requiring active treatment. Other significant ocular complications. Pregnancy or lactation. Known thyroid disorders. History or presence of thyroid neoplasms.
participants received subcutaneous semaglutide 0.25mg once weekly for 4 weeks followed by 0.5mg once weekly for 12 weeks, for a total treatment duration of 16 weeks
Peshawar, Khyber Pakhtunkhwa 25000, Pakistan
Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial
ADJUnct Semaglutide Treatment in Type 1 Diabetes
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo in Drug-naïve Subjects With Type 2 Diabetes
"Efficacy of Once Weekly GLP 1 Analogue: Semaglutide. A Multicenter Experience From Pakistan."
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes